Hematology, Department of Biomedical Sciences, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy.
Crit Rev Oncol Hematol. 2015 Mar;93(3):237-45. doi: 10.1016/j.critrevonc.2014.10.009. Epub 2014 Oct 22.
The therapeutic scenario available for adult patients with acute myeloid leukemia (AML) has shown only partial progresses over the last few years. This is especially true for refractory and relapsed AML whose outcome is still extremely disappointing. In this context Clofarabine has offered new promising perspectives within first and second line protocols. This review will firstly describe the initial development in monotherapy, considering then the different potential combination strategies which include both polichemotherapeutic regimens and less conventional approaches with new generation drugs. The potential use of Clofarabine as induction treatment for patients candidate to stem cell transplantation and within conditioning regimens will be finally evaluated.
近年来，可供急性髓系白血病（AML）成年患者使用的治疗方案仅取得了部分进展。对于难治性和复发性 AML，情况更是如此，其预后仍然非常令人失望。在这种情况下，克拉屈滨在一线和二线方案中提供了新的有前途的前景。这篇综述将首先描述单药治疗的初步发展，然后考虑包括多药化疗方案和使用新一代药物的非传统方法在内的不同潜在联合策略。最后将评估克拉屈滨作为候选干细胞移植患者的诱导治疗以及在预处理方案中的潜在用途。
